The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

What it’s Used for
Tirzepatide is a dual GIP/GLP-1 receptor agonist that revolutionizes treatment for both type 2 diabetes and weight management. It’s the first medication to target both incretin pathways, providing superior results compared to single-receptor drugs.
Weight Loss – Glucose control – Cardiovascular Protection